A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy
Tsung‐I Hsu(Taipei Medical University), Jan‐Jong Hung(National Cheng Kung University), Wu‐Chou Su(National Cheng Kung University Hospital), Sin‐Jin Lin(National Kaohsiung University of Science and Technology), Wen‐Chang Chang(Taipei Medical University), Keduo Qian, Masuo Goto, Yi-Chang Wang(National Cheng Kung University), Yoshiki Kashiwada(Tokushima University), Qiang Wang(Sichuan University), Sang Yong Kim, Yu Zhao(Guangdong University of Technology), Chia-Yang Hung(National Cheng Kung University), Kuo‐Hsiung Lee(University of North Carolina at Chapel Hill), Ming-Derg Lai(National Cheng Kung University), Ying‐Jung Chen(National Cheng Kung University)
Cited by 33
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
|New England Journal of Medicine|2023|605
Leptin in human physiology and pathophysiology
|American Journal of Physiology-Endocrinology and Metabolism|2011|582